Early detection of Alzheimer’s is critical, as disease pathology begins to accumulate 10 to 15 years prior to the onset of cognitive symptoms. Early diagnosis would permit extremely valuable and currently unavailable prognostic information to families, and would ultimately facilitate preemptive treatment at a point where the disease is far more treatable. Alzeca’s agents are based on MRI and CT scanning, technologies that have highly significant advantages over current PET scan methods, including far lower cost and far broader availability world-wide, for screening and diagnosis of these disorders.
To date, Alzeca has been supported by private investors and grants to its academic partners from the Cure Alzheimer’s Fund, Alzheimer’s Association, NIH, and Alliance for NanoHealth. The company’s founders have over 25 years of experience in drug development. Alzeca leadership features world- renowned experts in diagnostic imaging innovation and clinical neuroscience, as well as a deep, experienced management team.